Suppr超能文献

一种A位点选择性蛋白二硫键异构酶A1抑制剂的特性分析。

Characterization of an A-Site Selective Protein Disulfide Isomerase A1 Inhibitor.

作者信息

Cole Kyle S, Grandjean Julia M D, Chen Kenny, Witt Collin H, O'Day Johanna, Shoulders Matthew D, Wiseman R Luke, Weerapana Eranthie

机构信息

Department of Chemistry , Boston College , Chestnut Hill , Massachusetts 02467 , United States.

Department of Molecular Medicine , The Scripps Research Institute , La Jolla , California 92037 , United States.

出版信息

Biochemistry. 2018 Apr 3;57(13):2035-2043. doi: 10.1021/acs.biochem.8b00178. Epub 2018 Mar 19.

Abstract

Protein disulfide isomerase A1 (PDIA1) is an endoplasmic reticulum (ER)-localized thiol-disulfide oxidoreductase that is an important folding catalyst for secretory pathway proteins. PDIA1 contains two active-site domains (a and a'), each containing a Cys-Gly-His-Cys (CGHC) active-site motif. The two active-site domains share 37% sequence identity and function independently to perform disulfide-bond reduction, oxidation, and isomerization. Numerous inhibitors for PDIA1 have been reported, yet the selectivity of these inhibitors toward the a and a' sites is poorly characterized. Here, we identify a potent and selective PDIA1 inhibitor, KSC-34, with 30-fold selectivity for the a site over the a' site. KSC-34 displays time-dependent inhibition of PDIA1 reductase activity in vitro with a k/ K of 9.66 × 10 M s and is selective for PDIA1 over other members of the PDI family, and other cellular cysteine-containing proteins. We provide the first cellular characterization of an a-site selective PDIA1 inhibitor and demonstrate that KSC-34 has minimal sustained effects on the cellular unfolded protein response, indicating that a-site inhibition does not induce global protein folding-associated ER stress. KSC-34 treatment significantly decreases the rate of secretion of a destabilized, amyloidogenic antibody light chain, thereby minimizing pathogenic amyloidogenic extracellular proteins that rely on high PDIA1 activity for proper folding and secretion. Given the poor understanding of the contribution of each PDIA1 active site to the (patho)physiological functions of PDIA1, site selective inhibitors like KSC-34 provide useful tools for delineating the pathological role and therapeutic potential of PDIA1.

摘要

蛋白质二硫键异构酶A1(PDIA1)是一种定位于内质网(ER)的硫醇-二硫键氧化还原酶,是分泌途径蛋白的重要折叠催化剂。PDIA1包含两个活性位点结构域(a和a'),每个结构域都含有一个半胱氨酸-甘氨酸-组氨酸-半胱氨酸(CGHC)活性位点基序。这两个活性位点结构域具有37%的序列同一性,并且独立发挥功能以进行二硫键还原、氧化和异构化。已经报道了许多针对PDIA1的抑制剂,然而这些抑制剂对a和a'位点的选择性却鲜有研究。在此,我们鉴定出一种强效且选择性的PDIA1抑制剂KSC-34,其对a位点的选择性比对a'位点高30倍。KSC-34在体外对PDIA1还原酶活性表现出时间依赖性抑制,其k/ K为9.66×10 M s,并且对PDIA1的选择性高于PDI家族的其他成员以及其他含细胞半胱氨酸的蛋白质。我们首次对a位点选择性PDIA1抑制剂进行了细胞特性研究,并证明KSC-34对细胞未折叠蛋白反应的持续影响极小,这表明a位点抑制不会诱导与全局蛋白质折叠相关的内质网应激。KSC-34处理显著降低了不稳定的淀粉样变性抗体轻链的分泌速率,从而减少了依赖高PDIA1活性进行正确折叠和分泌的致病性淀粉样变性细胞外蛋白。鉴于对每个PDIA1活性位点对PDIA1的(病理)生理功能的贡献了解不足,像KSC-34这样的位点选择性抑制剂为阐明PDIA1的病理作用和治疗潜力提供了有用的工具。

相似文献

4

引用本文的文献

本文引用的文献

8
Protein disulfide isomerase: a promising target for cancer therapy.蛋白质二硫键异构酶:一种有前景的癌症治疗靶点。
Drug Discov Today. 2014 Mar;19(3):222-40. doi: 10.1016/j.drudis.2013.10.017. Epub 2013 Oct 31.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验